Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

Author： Onar Arzu   Kocak Mehmet   Boyett James  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.19, Iss.3, 2009-05, pp. : 437-455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1660-1664

Bentham Science Publishers

Access to resources Recommend Favorite

Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size

By Ji Yuan  

Journal of Biopharmaceutical Statistics, Vol. 22, Iss. 6, 2012-11 ,pp. : 1206-1219

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng  

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

By  

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

By  

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite